Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have received an average recommendation of “Buy” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $21.25.

Several analysts have recently weighed in on ARTV shares. HC Wainwright started coverage on shares of Artiva Biotherapeutics in a research note on Monday. They set a “buy” rating and a $20.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in Artiva Biotherapeutics in the 3rd quarter valued at approximately $42,000. Franklin Resources Inc. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter valued at $7,435,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter valued at $623,000. Wellington Management Group LLP purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth about $2,912,000. Finally, Samsara BioCapital LLC purchased a new position in Artiva Biotherapeutics in the 3rd quarter valued at about $4,506,000.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $10.64 on Monday. The firm’s 50-day moving average price is $11.41. Artiva Biotherapeutics has a 12 month low of $9.68 and a 12 month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). As a group, equities analysts expect that Artiva Biotherapeutics will post -4.68 EPS for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.